Latest Conference Articles

Ophthalmology Times®' EyeCon co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute, and glaucoma specialist Oluwatosin U. Smith MD, from Glaucoma Associates of Texas, discuss some of the highlights of EyeCon 2022.

Stephen Pflugfelder, MD, professor and director of the Ocular Surface Center at Baylor College of Medicine in Houston, Texas, presents a challenging diagnostic dilemma.

Rishi Singh, MD, of Cleveland Clinic Florida, touches upon the various advancements that are making a difference for clinicians and patients and reducing their progression in this disease state.

Julius Oatts, MD, covered a range of current considerations for retinopathy of prematurity (ROP), including the updated International Classification for ROP, clinical research, and some of the socioeconomic factors that affect ROP. Oatts is assistant professor and associate residency program director with the Department of Ophthalmology at the University of California, San Francisco.

The groups invite those attending the annual conference to join them at their event on Monday, January 16, which is free to OWL and WIO members.

This December, the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide attendees with an end-of-year opportunity to meet their continuing medical education requirements. This activity has been approved for 12.50 AMA PRA Category 1 Credits™.

RGX-314 continues to be well tolerated in 50 patients from Cohorts 1-3 with no drug-related serious adverse events. The Phase II trial will be expanded to include higher third dose level, with patients stratified by DRSS levels across cohorts and all receiving short-course prophylactic ocular steroids following RGX-314 administration.

New details define the molecular patterns in thyroid eye disease and further implicate the role of insulin-like growth factor-1 in patients with low Clinical Activity Scores.

Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, highlights the Phase 1 and Phase 2 DAVIO clinical trials for EYP-1901 in wet age-related macular degeneration. The company also announced the first patient has been dosed in the Phase 2 PAVIA trial of EYP-1901 for nonproliferative diabetic retinopathy.

Lawrence Whittle, Chief Commercial Officer for Verana Health, explains what the significance of imaging data linked with electronic health record data means for patient outcomes.

Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.

Marc Berger, Chief Operating Officer at Verana Health, highlights what a new initiative with the American Academy of Ophthalmology IRIS Registry will mean for patients and physicians.

Lloyd Paul Aiello, MD, moderated a panel at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago that focused on diabetic retinopathy. He shares some of the highlights of this session.

Marjan Farid, MD, discussed the latest updates in femtosecond laser keratoplasty during a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago. She shared the highlights of that presentation here.

Arun Singh, MD, discusses a presentation on iris lesions he gave recently at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago on the use of small incision garden hydroaspiration of iris lesions.

CEO Rob Thornhill discusses the features of the device, as well as plans for a new technology called ZEPTOLINK which combines the company’s novel ZEPTO technology with any phaco device.

Complimentary registration is open for this unique meeting designed to prepare young ophthalmologists for success in early practice.

Harit Bhatt, MD, a Chicagoland-area retinal surgeon, shared his experience with the LEAF and LION portable lasers during a conversation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago.

Vivek Patel, MD, discusses issues that could threaten sight during presentation at the American Academy of Ophthalmology annual meeting in Chicago.

Ula V. Jurkunas, MD, discusses a presentation she gave recently at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago on the use of limbal stem cells to treat corneal blindness.

Michelle Senchyna, PhD, provided an update of the COMET program and other development activities at Aerie Pharmaceuticals during a conversation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago.

During a conversation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, Rishi Singh, MD, offered highlights of the two-year results of faricimab in a pair of phase 3 clinical trials.

According to Penny Asbell, MD, FACS, MBA, the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study has identified high levels of in vitro antibiotic resistance among ocular staphylococcal and pneumococcal pathogens, resistance that may affect treatment success. She discussed the program at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago.

At AAO, Kamran Riaz, MD, discussed the new textbook, "Optics for the New Millennium," which is intended to be a compendium resource for ophthalmologists.

Harvey Uy, MD, has been using the Ally adaptive cataract treatment system at his clinic in the Philippines, and it is allowing him to be more efficient.

Jeff Nau, PhD, MMS, President and CEO of Oyster Point Pharmaceuticals, provides an appraisal of the company's pipeline as well as updates on recent innovations to hit the market.

Meghan Berkenstock, MD, presented a paper at AAO titled “Effectiveness of Durezol as Additional Agent to Systemic Medications for Treatment of Scleritis,” and shared the highlights in a conversation with Ophthalmology Times.®

Kathryn A. Colby, MD, PhD, discusses highlights of the World Cornea Congress, which was held recently in Chicago.

Mike Lyons, PHR, MHRIR, and Megan Odell, BHA, MHHR, with Austin Retina Associates, outline how to implement the GREAT and the LEAP method for an improved employee and patient experience.

NovaSight’s CureSight is a digital device that proved in a pivotal study to be non-inferior to patching, according to the company.